Metabolic syndrome and endothelial dysfunction

Alessia Fornoni, Leopoldo Raij

Research output: Contribution to journalArticle

57 Citations (Scopus)

Abstract

The incidence of metabolic syndrome is rapidly increasing in the United States. Metabolic syndrome is associated with increased cardiovascular morbidity and mortality, and endothelial dysfunction is an early pathogenetic event in the metabolic syndrome. Endothelial dysfunction of either the coronary, the peripheral, or the cerebral vasculature is a predictor of vascular events and appears to be a marker of uncontrolled atherosclerotic risk that adds to the burden of the genetic predisposition to cardiovascular disease. Clinically and experimentally, endothelial dysfunction can be restored by several agents, including blockers/inhibitors of the renin-angiotensin-aldosterone system, as well as statins. Nevertheless, it would be premature, and most likely inappropriate, to use improvement of endothelial function as a surrogate end point to predict reduction in cardiovascular morbidity and mortality. However, a clear understanding of the mechanisms of endothelial dysfunction in the metabolic syndrome may allow the development of preventive and early therapeutic measures targeting cardiovascular disease.

Original languageEnglish
Pages (from-to)88-95
Number of pages8
JournalCurrent Hypertension Reports
Volume7
Issue number2
StatePublished - Apr 1 2005

Fingerprint

Cardiovascular Diseases
Morbidity
Hydroxymethylglutaryl-CoA Reductase Inhibitors
Mortality
Genetic Predisposition to Disease
Renin-Angiotensin System
Blood Vessels
Biomarkers
Incidence
Therapeutics

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

Metabolic syndrome and endothelial dysfunction. / Fornoni, Alessia; Raij, Leopoldo.

In: Current Hypertension Reports, Vol. 7, No. 2, 01.04.2005, p. 88-95.

Research output: Contribution to journalArticle

Fornoni, Alessia ; Raij, Leopoldo. / Metabolic syndrome and endothelial dysfunction. In: Current Hypertension Reports. 2005 ; Vol. 7, No. 2. pp. 88-95.
@article{d77a8eafdf214426ac58aae1b362824c,
title = "Metabolic syndrome and endothelial dysfunction",
abstract = "The incidence of metabolic syndrome is rapidly increasing in the United States. Metabolic syndrome is associated with increased cardiovascular morbidity and mortality, and endothelial dysfunction is an early pathogenetic event in the metabolic syndrome. Endothelial dysfunction of either the coronary, the peripheral, or the cerebral vasculature is a predictor of vascular events and appears to be a marker of uncontrolled atherosclerotic risk that adds to the burden of the genetic predisposition to cardiovascular disease. Clinically and experimentally, endothelial dysfunction can be restored by several agents, including blockers/inhibitors of the renin-angiotensin-aldosterone system, as well as statins. Nevertheless, it would be premature, and most likely inappropriate, to use improvement of endothelial function as a surrogate end point to predict reduction in cardiovascular morbidity and mortality. However, a clear understanding of the mechanisms of endothelial dysfunction in the metabolic syndrome may allow the development of preventive and early therapeutic measures targeting cardiovascular disease.",
author = "Alessia Fornoni and Leopoldo Raij",
year = "2005",
month = "4",
day = "1",
language = "English",
volume = "7",
pages = "88--95",
journal = "Current Hypertension Reports",
issn = "1522-6417",
publisher = "Current Medicine Group",
number = "2",

}

TY - JOUR

T1 - Metabolic syndrome and endothelial dysfunction

AU - Fornoni, Alessia

AU - Raij, Leopoldo

PY - 2005/4/1

Y1 - 2005/4/1

N2 - The incidence of metabolic syndrome is rapidly increasing in the United States. Metabolic syndrome is associated with increased cardiovascular morbidity and mortality, and endothelial dysfunction is an early pathogenetic event in the metabolic syndrome. Endothelial dysfunction of either the coronary, the peripheral, or the cerebral vasculature is a predictor of vascular events and appears to be a marker of uncontrolled atherosclerotic risk that adds to the burden of the genetic predisposition to cardiovascular disease. Clinically and experimentally, endothelial dysfunction can be restored by several agents, including blockers/inhibitors of the renin-angiotensin-aldosterone system, as well as statins. Nevertheless, it would be premature, and most likely inappropriate, to use improvement of endothelial function as a surrogate end point to predict reduction in cardiovascular morbidity and mortality. However, a clear understanding of the mechanisms of endothelial dysfunction in the metabolic syndrome may allow the development of preventive and early therapeutic measures targeting cardiovascular disease.

AB - The incidence of metabolic syndrome is rapidly increasing in the United States. Metabolic syndrome is associated with increased cardiovascular morbidity and mortality, and endothelial dysfunction is an early pathogenetic event in the metabolic syndrome. Endothelial dysfunction of either the coronary, the peripheral, or the cerebral vasculature is a predictor of vascular events and appears to be a marker of uncontrolled atherosclerotic risk that adds to the burden of the genetic predisposition to cardiovascular disease. Clinically and experimentally, endothelial dysfunction can be restored by several agents, including blockers/inhibitors of the renin-angiotensin-aldosterone system, as well as statins. Nevertheless, it would be premature, and most likely inappropriate, to use improvement of endothelial function as a surrogate end point to predict reduction in cardiovascular morbidity and mortality. However, a clear understanding of the mechanisms of endothelial dysfunction in the metabolic syndrome may allow the development of preventive and early therapeutic measures targeting cardiovascular disease.

UR - http://www.scopus.com/inward/record.url?scp=20444396168&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=20444396168&partnerID=8YFLogxK

M3 - Article

C2 - 15748531

AN - SCOPUS:20444396168

VL - 7

SP - 88

EP - 95

JO - Current Hypertension Reports

JF - Current Hypertension Reports

SN - 1522-6417

IS - 2

ER -